Who are Trastuzumab + Pertuzumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pertuzumab + trastuzumab, Pertuzumab and Trastuzumab, FDC of Pertuzumab and Trastuzumab SC, Pertuzumab and Trastuzumab FDC SC, Docetaxel combined + Trastuzumab +Pertuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-pertuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Trastuzumab + Pertuzumab — Competitive Intelligence Brief

Trastuzumab + Pertuzumab (Trastuzumab + Pertuzumab) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeted monoclonal antibody combination. Area: Oncology.

marketed HER2-targeted monoclonal antibody combination HER2 (human epidermal growth factor receptor 2) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab + Pertuzumab (Trastuzumab + Pertuzumab) — Massachusetts General Hospital. Trastuzumab and pertuzumab are monoclonal antibodies that block HER2 signaling by binding to different epitopes on the HER2 receptor, preventing tumor cell growth in HER2-positive cancers.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Trastuzumab + Pertuzumab TARGET	Trastuzumab + Pertuzumab	Massachusetts General Hospital	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab	Pertuzumab and Trastuzumab	QuantumLeap Healthcare Collaborative	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
FDC of Pertuzumab and Trastuzumab SC	FDC of Pertuzumab and Trastuzumab SC	Hoffmann-La Roche	phase 3	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Pertuzumab and Trastuzumab FDC SC	Pertuzumab and Trastuzumab FDC SC	Hoffmann-La Roche	phase 3	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)
Docetaxel combined + Trastuzumab +Pertuzumab	Docetaxel combined + Trastuzumab +Pertuzumab	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	phase 3	Chemotherapy + HER2-targeted monoclonal antibody combination	HER2 (trastuzumab and pertuzumab); microtubule stabilization (docetaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeted monoclonal antibody combination class)

Hoffmann-La Roche · 2 drugs in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
QuantumLeap Healthcare Collaborative · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab + Pertuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-pertuzumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab